Foreign R&D-Based MNCs Prod China To Shorten Drug Review Process
This article was originally published in PharmAsia News
Executive Summary
Foreign drug makers are urging China to reduce the time it takes regulators to review their products for marketing approval as one way to spur more innovation in the country.